First Department of Internal Medicine, Toyama University Hospital, Toyama City, Japan.
Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama City, Japan.
Thorac Cancer. 2023 Jun;14(17):1618-1623. doi: 10.1111/1759-7714.14907. Epub 2023 Apr 26.
Studies have suggested the potential efficacy of immune checkpoint inhibitors (ICIs) for pulmonary sarcomatoid carcinoma. This multicenter observational study was conducted to evaluate the efficacy of systemic ICI therapy and chemoradiation followed by durvalumab therapy for pulmonary sarcomatoid carcinoma.
We analyzed the data of patients with pulmonary sarcomatoid carcinoma who received systemic ICI therapy or chemoradiation followed by durvalumab therapy between 2016 and 2022.
In this study, data of a total of 22 patients who received systemic ICI therapy and four patients who received chemoradiation followed by durvalumab therapy were analyzed. In the patients who received systemic ICI therapy, the median progression-free survival after initiation of therapy was 9.6 months, and the overall survival did not reach the median. The 1-year progression-free survival rate and overall survival rate were estimated to be 45.5% and 50.1%, respectively. Although the log-rank test revealed no significant association between the tumor expression level of programmed death ligand-1 (tumor proportion score evaluated using 22C3 antibody: ≥50% vs. <50%) and the survival duration, the majority of patients showing long-term survival showed a tumor proportion score of ≥50%. Of four patients treated with chemoradiation followed by durvalumab therapy, two patients showed an overall survival of ≥30 months, whereas the remaining two patients died within 12 months.
The progression-free survival of patients who received systemic ICI therapy was 9.6 months, suggesting that ICI therapy might be effective in patients with pulmonary sarcomatoid carcinoma.
研究表明免疫检查点抑制剂（ICIs）对肺肉瘤样癌可能有效。本多中心观察性研究旨在评估系统ICI 治疗联合放化疗序贯度伐利尤单抗治疗肺肉瘤样癌的疗效。
我们分析了 2016 年至 2022 年间接受系统ICI 治疗或放化疗序贯度伐利尤单抗治疗的肺肉瘤样癌患者的数据。
本研究共分析了 22 例接受系统 ICI 治疗和 4 例接受放化疗序贯度伐利尤单抗治疗的患者的数据。在接受系统 ICI 治疗的患者中，起始治疗后无进展生存期的中位数为 9.6 个月，总生存期未达到中位数。1 年无进展生存率和总生存率估计分别为 45.5%和 50.1%。虽然对数秩检验未显示程序性死亡配体 1（肿瘤比例评分，使用 22C3 抗体评估：≥50%与<50%）的肿瘤表达水平与生存时间之间存在显著关联，但大多数长期生存的患者肿瘤比例评分≥50%。在接受放化疗序贯度伐利尤单抗治疗的 4 例患者中，2 例患者的总生存期≥30 个月，而其余 2 例患者在 12 个月内死亡。
接受系统 ICI 治疗的患者无进展生存期为 9.6 个月，提示 ICI 治疗可能对肺肉瘤样癌患者有效。
